Gwen Macdonald
Allschwil, BL, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Characteristics, Treatment Patterns and Outcomes of Patients with Pulmonary Arterial Hypertension by Race and Ethnicity Using Real-World Data from the Combined OPUS/OrPHeUS Studies.
Journal: Advances in therapy
Published: August 14, 2025
Macitentan and Tadalafil Combination Therapy in Patients with Pulmonary Arterial Hypertension and Cardiovascular Comorbidities: Real-World Evidence from OPUS and OrPHeUS.
Journal: Advances in therapy
Published: November 12, 2024
Macitentan and Tadalafil Combination Therapy in Incident and Prevalent Pulmonary Arterial Hypertension: Real-World Evidence from the OPUS/OrPHeUS Studies.
Journal: Advances in therapy
Published: May 23, 2024
Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities.
Journal: European journal of heart failure
Published: January 26, 2024
Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies.
Journal: Pulmonary therapy
Published: October 16, 2023
Comparison of cardiac magnetic resonance imaging, functional and haemodynamic variables in pulmonary arterial hypertension: insights from REPAIR.
Journal: ERJ open research
Published: July 28, 2023
Memo interacts with c-Src to control Estrogen Receptor alpha sub-cellular localization.
Journal: Oncotarget
Published: June 30, 2016
Memo is a copper-dependent redox protein with an essential role in migration and metastasis.
Journal: Science signaling
Published: June 12, 2014
Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion.
Journal: Breast cancer research : BCR
Published: July 26, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026